Market Insights:
The emergence
of versatile gene editing technologies in recent years has enabled researchers
to economically and seamlessly introduce sequence-specific modifications into
genomes of a wide range of organisms and cell types. Some of the prevalent core
technologies in the field are transcription activator-like effector nucleases
(TALENs), homing endonucleases or meganucleases, clustered regularly
interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9
(Cas9), and zinc-finger nucleases (ZFNs).
This
increasing interest in pharmaceutical applications of gene editing is boosting
the growth of the market; however, recent developments in the sector have also
raised some concerns. Back in 2015, researchers conducted the first experiment
to modify human embryos, which kickstarted further investigation into human
genome editing. A recent series of experiments published on bioRxiv has raised
some safety concerns about DNA changes and on-target complexities following
CRISPR-Cas9 genome editing. The field demands much more investigation before it
can be scaled. Since CRISPR is a prominent contributor to the overall revenue
of the gene editing industry, unfavorable research findings might hinder the
growth of the gene editing market for a few years.
Other leading companies operating in the market include Thermo Fisher Scientific, Lonza, GenScript, Vigene Biosciences, Transposagen Biopharmaceuticals, Genecopoeia, Calyxt, Editas Medicine, EpiGenie, and Editas Medicine. Intellia Therapeutics is also a company working on CRISPR-Cas9 gene editing to develop genome editing treatments to cure genetic diseases. U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has just given the green light to a Phase 1 clinical trial for Intellia’s NTLA-2001 gene therapy for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). With companies investing and exploring further into the applications of gene editing, the market is expected to exhibit significant research-backed growth in the coming years.
No comments:
Post a Comment